Gilead Sciences, Inc. GILD announced that the investigational single-tablet regimen of bictegravir and lenacapavir for the ...

Compounding that statistic, prior studies indicate some trans people at high risk for HIV transmission are hesitant to take ...

With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...

Key PointsResearch on HIV's conical capsid that began over 25 years ago led to the development of lenacapavir, the world's ...

Gilead Sciences (GILD) just cleared an important milestone: its once daily bictegravir and lenacapavir combo matched Biktarvy ...

Gilead Sciences said on Monday its experimental HIV treatment met the main goal in a late-stage trial. The treatment regimen ...

The Trump administration's funding cuts to PEPFAR and USAID disrupted global HIV treatment and prevention, threatening progress made over decades. Lenacapavir's FDA approval as a long-acting ...

Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.

Investigational Treatment Regimen Could Expand Options for Virologically Suppressed Adults –– Positive Phase 3 Results from ...

– European Commission Grants Marketing Authorization for Sunlenca, Helping to Address a Critical Unmet Clinical Need for People with Multi-Drug-Resistant HIV Who Have Very Limited Treatment Choices – ...

Please provide your email address to receive an email when new articles are posted on . Twice-yearly lenacapavir injections reduced HIV infections by 96% in a phase 3 trial. Gilead Sciences will begin ...

Gilead Sciences, Inc. announced that Keeley Wettan has been appointed executive vice president and general counsel, Legal & Compliance, effective immediately, the biopharmaceutical company said ...